www.fdanews.com/articles/88497-trans-genic-and-kumamoto-foundation-conclude-anti-hiv-antibody-license
TRANS GENIC AND KUMAMOTO FOUNDATION CONCLUDE ANTI-HIV ANTIBODY LICENSE
July 19, 2006
Trans Genic, a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046. The partners have produced a monoclonal antibody with a high level of neutralization activity against HIV as part of a therapeutic drug for AIDS.
Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5268/118/)